Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...